{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:47:34Z","timestamp":1768268854431,"version":"3.49.0"},"reference-count":20,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,6,17]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.<\/jats:p>","DOI":"10.1136\/bcr-2021-242199","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T12:44:55Z","timestamp":1625661895000},"page":"e242199","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event"],"prefix":"10.1136","volume":"14","author":[{"given":"Khalid","family":"Rashid","sequence":"first","affiliation":[{"name":"Department of General Medicine, Northampton General Hospital NHS Trust, Northampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Aamir","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Acute Medicine, Northampton General Hospital, Northampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafeez Ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, City University of Science and Information Technology, Peshawar, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Naser","family":"Elzouki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamad Medical Corporation Department of Medical Education, Doha, Qatar"},{"name":"Qatar University College of Medicine, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"2025082704040756000_14.7.e242199.1","unstructured":"British Heart Foundation . UK Factsheet, 2021. Available: https:\/\/www.bhf.org.uk\/what-we-do\/news-from-the-bhf\/contact-the-press-office\/facts-and-figures"},{"key":"2025082704040756000_14.7.e242199.2","unstructured":"National Institute for Health and Care Excellence . Acute Coronary Syndrome [NICE guideline No. 185], 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ng185"},{"key":"2025082704040756000_14.7.e242199.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.053"},{"key":"2025082704040756000_14.7.e242199.4","doi-asserted-by":"crossref","unstructured":"Schmucker J , Fach A , Mata Marin LA , et al . Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST\u2010Segment\u2013Elevation myocardial infarctions. J Am Heart Assoc 2019;8.doi:10.1161\/JAHA.119.012530","DOI":"10.1161\/JAHA.119.012530"},{"key":"2025082704040756000_14.7.e242199.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"2025082704040756000_14.7.e242199.6","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"Corrigendum to: 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of cardiology (ESC)","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2025082704040756000_14.7.e242199.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611688"},{"key":"2025082704040756000_14.7.e242199.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"2025082704040756000_14.7.e242199.9","first-page":"4","article-title":"Brilinta\u2122 (ticagrelor) Tablets: A P2Y(12) platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS)","volume":"37","year":"2012","journal-title":"P T"},{"key":"2025082704040756000_14.7.e242199.10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40256-015-0108-5","article-title":"Ticagrelor: a review of its use in adults with acute coronary syndromes","volume":"15","author":"Dhillon","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025082704040756000_14.7.e242199.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132"},{"key":"2025082704040756000_14.7.e242199.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603060"},{"key":"2025082704040756000_14.7.e242199.13","article-title":"Ticagrelor-induced diarrhea in a patient with acute coronary syndrome requiring percutaneous coronary artery intervention","volume":"11","author":"Alomari","year":"2019","journal-title":"Cureus"},{"key":"2025082704040756000_14.7.e242199.14","doi-asserted-by":"crossref","first-page":"S1049","DOI":"10.14309\/00000434-201810001-01849","article-title":"Premature ticagrelor discontinuation secondary to severe diarrhea: a case report","volume":"113","author":"momani","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2025082704040756000_14.7.e242199.15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00392-013-0552-7","article-title":"Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany","volume":"102","author":"Theidel","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2025082704040756000_14.7.e242199.16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40273-017-0607-0","article-title":"Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Pouwels","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2025082704040756000_14.7.e242199.17","doi-asserted-by":"publisher","DOI":"10.1159\/000350961"},{"key":"2025082704040756000_14.7.e242199.18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"2025082704040756000_14.7.e242199.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30325-1"},{"key":"2025082704040756000_14.7.e242199.20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1160\/TH09-10-0695","article-title":"The Triton versus Plato trials: differences beyond platelet inhibition","volume":"103","author":"Serebruany","year":"2010","journal-title":"Thromb Haemost"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-242199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:04:17Z","timestamp":1756292657000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-242199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,7]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bcr-2021-242199"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-242199","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}